title: Renal hypersensitivity vasculitis associated with dapsone.
abstract: We describe clinical and pathological features of kidney and skin involvement in a patient with hypersensitivity vasculitis associated with dapsone. Although visceral damage occurs rarely, similar skin and kidney histopathologic and immunohistochemical findings indicate that this organ is a target for type IV cell-mediated dapsone reaction. To our knowledge, this is the first reported case of renal hypersensitivity vasculitis associated with dapsone.
authors.affiliation: Departamento de Clínica Médica, Hospital Universitário Júlio Müller, Universidade Federal de Mato Grosso, Cuiabá, Brazil.
authors.forename: Edson N
authors.initials: EN
authors.lastname: Alves-Rodrigues
authors.forename: Luciano C
authors.initials: LC
authors.lastname: Ribeiro
authors.forename: Margareth D
authors.initials: MD
authors.lastname: Silva
authors.forename: Arley
authors.initials: A
authors.lastname: Takiuchi
authors.forename: Osvaldo C
authors.initials: OC
authors.lastname: Rabel-Filho
authors.forename: Dino
authors.initials: D
authors.lastname: Martini-Filho
authors.forename: Cor J F
authors.initials: CJ
authors.lastname: Fontes
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents; D000995:Antitubercular Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002991:Clofazimine / Q000008:administration & dosage / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D003622:Dapsone / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D004342:Drug Hypersensitivity / Q000188:drug therapy / Q000209:etiology*; D004359:Drug Therapy, Combination / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007674:Kidney Diseases / Q000139:chemically induced* / Q000188:drug therapy; D007917:Leprostatic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D007918:Leprosy / Q000188:drug therapy; D008775:Methylprednisolone / Q000008:administration & dosage / Q000627:therapeutic use; D012293:Rifampin / Q000008:administration & dosage / Q000627:therapeutic use; D014397:Tuberculosis, Pulmonary / Q000150:complications / Q000188:drug therapy; D018366:Vasculitis, Leukocytoclastic, Cutaneous / Q000139:chemically induced* / Q000188:drug therapy
chemical_list: D000900:Anti-Bacterial Agents; D000995:Antitubercular Agents; D007166:Immunosuppressive Agents; D007917:Leprostatic Agents; D003520:Cyclophosphamide; D003622:Dapsone; D002991:Clofazimine; D012293:Rifampin; D008775:Methylprednisolone